We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+56.31%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.28B
AUM Growth
+$186M
Cap. Flow
+$21.2M
Cap. Flow %
0.93%
Top 10 Hldgs %
55.42%
Holding
67
New
19
Increased
9
Reduced
10
Closed
10

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$49.9M
2
TRML
Tourmaline Bio
TRML
+$44.1M
3
CGON icon
CG Oncology
CGON
+$32.7M
4
NAMS icon
NewAmsterdam Pharma
NAMS
+$30.4M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$30.4M

Top Sells

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$160M
2
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$75.4M
3
IMVT icon
Immunovant
IMVT
+$49.1M
4
CBAY
Cymabay Therapeutics
CBAY
+$42.5M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$34.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHRS icon
51
GH Research
GHRS
$2.08B
$6.32M 0.28%
593,043
– –
STOK icon
52
Stoke Therapeutics
STOK
$2.11B
$5.77M 0.25%
427,163
-660,644
-61% -$4M
LNTH icon
53
Lantheus
LNTH
$6.59B
$4.67M 0.2%
75,000
– –
VERV
54
DELISTED
Verve Therapeutics
VERV
$4.65M 0.2%
350,000
– –
RAPT
55
DELISTED
RAPT Therapeutics
RAPT
$4.46M 0.2%
62,094
– –
YARW
56
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$4.28M 0.19%
27,887
– –
BCAB icon
57
BioAtla
BCAB
$5.74M
$4.03M 0.18%
23,417
-205
-0.9% -$25.5K
EDIT icon
58
PUT
Editas Medicine
EDIT
$442M
– –
-500,000
Closed -$5.07M
IMVT icon
59
Immunovant
IMVT
$8.25B
– –
-1,165,000
Closed -$49.1M
NMRA icon
60
Neumora Therapeutics
NMRA
$302M
– –
-92,293
Closed -$1.57M
OLMA icon
61
Olema Pharmaceuticals
OLMA
$1.05B
– –
-2,456,800
Closed -$34.5M
SNDX icon
62
Syndax Pharmaceuticals
SNDX
$1.82B
– –
-1,175,000
Closed -$25.4M
AXNX
63
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-250,000
Closed -$15.6M
CBAY
64
DELISTED
Cymabay Therapeutics
CBAY
– –
-1,800,000
Closed -$42.5M
AMAM
65
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-11,231,000
Closed -$160M
RYZB
66
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-1,213,478
Closed -$75.4M
HARP
67
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-2,349,060
Closed -$22.6M
1 2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Cormorant Asset Management held 67 positions worth $2.28B, up 8.9% from $2.09B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Cormorant Asset Management's Q1 2024 filing shows 19 new, 9 increased, 10 reduced and 10 closed positions. Its largest new stake was Corbus Pharmaceuticals: 2,025,000 shares worth $79.5M. The largest sale was Ambrx Biopharma Inc, an estimated $160M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

  • Cormorant Asset Management's largest Q1 2024 buy was Corbus Pharmaceuticals: 2,025,000 shares worth $79.5M.
  • Cormorant Asset Management added most to Praxis Precision Medicines in Q1 2024, an estimated $30.4M increase.
  • Cormorant Asset Management's biggest Q1 2024 reduction was Spyre Therapeutics, cutting an estimated $19.9M.
  • Cormorant Asset Management fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $160M.
  • Cormorant Asset Management's ten largest holdings make up 55% of its $2.28B portfolio in Q1 2024.
  • Cormorant Asset Management opened 19 new positions and closed 10 in Q1 2024.
  • Cormorant Asset Management's portfolio value rose 8.9% quarter-over-quarter to $2.28B.

Based on Cormorant Asset Management's 13F filing for Q1 2024, filed 15 May 2024.